Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.
Lopes, Renato D; Heizer, Gretchen; Aronson, Ronald; Vora, Amit N; Massaro, Tyler; Mehran, Roxana; Goodman, Shaun G; Windecker, Stephan; Darius, Harald; Li, Jia; Averkov, Oleg; Bahit, M Cecilia; Berwanger, Otavio; Budaj, Andrzej; Hijazi, Ziad; Parkhomenko, Alexander; Sinnaeve, Peter; Storey, Robert F; Thiele, Holger; Vinereanu, Dragos; Granger, Christopher B; Alexander, John H.
N Engl J Med
; 380(16): 1509-1524, 2019 04 18.
Artigo em Inglês | MEDLINE | ID: mdl-30883055
Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy.
Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial.
Apixaban with antiplatelet therapy after acute coronary syndrome.
The need for novel anticoagulation therapy in acute coronary syndrome.
A retrospective analysis of the periprocedural management of oral anticoagulants in patients undergoing interventional radiology procedures.
Prescribing of NOACs has outnumbered warfarin: exploring how physicians choose anticoagulant treatments.
Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison.
Apixaban after acute coronary syndrome.
Apixaban (Eliquis) in deep vein thrombosis and pulmonary embolism. Warfarin remains the standard therapy.
Apixaban or enoxaparin for thromboprophylaxis after knee replacement.